虚血性心疾患における脂質代謝と凝固・線溶系の関係とその臨床的意義

缺血性心脏病脂质代谢与凝血/纤溶系统的关系及其临床意义

• 批准号: 06770522
• 负责人: 中山 浩
• 金额: $ 0.58万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Encouragement of Young Scientists (A)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-06770522/
• 关键词: 急性心筋梗塞; 不安定狭心症; 接着分子; GMP-140

急性心筋梗塞や不安定狭心症の発症に冠動脈血栓や冠攣縮が関連し、この発症過程に血管内皮、血小板および白血球との相互作用が重要な役割を果たしている。この細胞間相互作用の第一段階として接着分子機構が注目されている。一方、granule membrane protein-140(GMP-140)は血小板や血管内皮細胞の分泌顆粒膜蛋白で白血球接着の標的として機能する。そこで、急性心筋梗塞や不安定狭心症例における可溶性のGMP-140を経時的に測定し、その臨床的意義について検討した。対象は、心筋梗塞群でt-PA(tissue-type plasminogen activator)使用群9例、t-PA非使用群7例、健常人10例の3群に分け、心筋梗塞群では発症24時間以内、24〜48時間、48〜72時間,さらに安定狭心症が増悪した入院患者6例で心電図変化を伴う狭心症発作後1時間以内、3時間後、および5時間以降に、また労作狭心症6例に多段階運動負荷試験を施行し、負荷前後で可溶性GMP-140を免疫学的酵素抗体法にて測定した。急性心筋梗塞群のGMP-140は、t-PA使用の有無にかかわらず対照群に比較して、有意に高値であった。さらに急性心筋梗塞群ではt-PA使用群のGMP-140が、t-PA非使用群に比較して、有意に低値であった。不安定狭心症発作後のGMP-140は、1時間以内、3時間後で対照群と比較し有為に高値を示したが、5時間以後では、対照群と差はなかった。労作狭心症では運動負荷にて胸痛を認めたが負荷直後および1時間後のGMP-140は、対照群と差がなかった。以上より、急性心筋梗塞発症や不安定狭心症過程に血管内皮細胞-血小板-白血球間の接着機構が存在していることが示唆された。さらにt-PA使用の有無によるGMP-140の放出反応の違いは血栓溶解による血小板接着能の改善と関連しているものと推測された。なお、血中t-PA測定は、有意差を認めなかった。

Acute myocardial infarction, unstable heart disease, acute heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, The first stage of the intercellular interaction is followed by the attention of the molecular institutions. On the one hand, granule membrane protein-140 (GMP-140) platelets and vascular endothelial cells secrete granule membrane protein (GMP) and white blood cells (WBC). Acute Myocardial Infarction, Acute Myocardial Infarction, unstable Stenosis, Acute Myocardial Infarction, Acute Myocardial Infarction There were 9 cases of t-PA (tissue-type plasminogen activator), 7 cases of t-PA non-user group, 10 cases of normal person and 24 hours, 48 hours, 48 hours and 72 hours in patients with myocardial infarction group. There were 6 patients with stable heart disease, 6 patients with valium, 6 patients with heart disease, 6 patients with heart disease, 6 patients with valium, 6 patients with heart disease, 6 patients with heart disease, 6 patients with valium, 6 patients with heart disease, 6 patients with heart disease Acute myocardial infarction group "GMP-140", t-PA use "you", "you", you, you, you, Patients with acute myocardial infarction, t-PA users, t-PA non-users, patients with acute myocardial infarction, patients with acute myocardial infarction and patients with acute myocardial infarction. After the onset of unstable heart disease, GMP-140 was normal, within 1 hour, 3 hours later, after 5 hours, and after 5 hours, the results showed that there was no significant difference between the two groups. Make the exercise of narrow heart disease, exercise, chest pain, chest pain and chest pain. Acute myocardial infarction, acute myocardial infarction, unstable heart disease, vascular endothelial cell-platelet-white blood cell count in the course of acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart disease, acute myocardial infarction, unstable heart T-PA uses antithrombotic thrombolysis to release antithrombotic platelets that can then improve thrombolysis by using GMP-140. Determination of t-PA in blood and intentional differential diagnosis.